IGM Biosciences pivoted to autoimmune disease, reducing R&D expenses. The company reported a net loss of $61.4 million. CEO ...

Stifel raised the firm’s price target on IGM Biosciences (IGMS) to $27 from $25 and keeps a Buy rating on the shares. The firm believes management’s ability to provide a preliminary mid-FY25 update ...

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on IGM Biosciences (IGMS – Research Report) today and set a price target ...

Revenue exceeded analyst estimates by 113%. Earnings per share (EPS) missed analyst estimates by 24%. Looking ahead, revenue ...

IGM Biosciences (NASDAQ:IGMS – Free Report) had its price objective increased by Royal Bank of Canada from $17.00 to $20.00 in a research note published on Friday morning, Benzinga reports.

The company’s 50 day moving average is $14.23 and its 200-day moving average is $10.74. IGM Biosciences has a 12 month low of $3.81 and a 12 month high of $22.50. The firm has a market cap of $1 ...

Since it has a market capitalisation of US$939m, IGM Biosciences' US$176m in cash burn equates to about 19% of its market value. As a result, we'd venture that the company could raise more cash for ...

MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM ...

IGM Biosciences, Inc. (NASDAQ:IGMS), a biotechnology company focused on developing treatments for autoimmune diseases, has recently undergone a significant strategic shift that has caught the ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.